tumor
Conditions
Interventions
Sponsors
Hebei General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Understand the research procedure and voluntarily sign the informed consent to participate in the study; 2. Subjects >=18 years of age undergoing tumor treatment; 3. Meet the following diagnostic criteria: (1) Peripheral blood platelet count < 100×10^9/L; (2) Before the onset of the disease, certain chemotherapy drugs that can cause thrombocytopenia (or tumor targeting, immune and other therapeutic drugs) should be used, and the symptoms and signs caused by thrombocytopenia gradually reduce or the platelet count returns to normal after the withdrawal of the drug; (3) To exclude other causes of thrombocytopenia, especially the underlying lesions and comorbidities, such as aplastic anemia, acute leukemia, radiation sickness, immune thrombocytopenia, hypersplenia and bone marrow tumor cell infiltration; (4) Exclude the use of non-anti-tumor (including chemotherapy, targeting, immunotherapy, etc.) drugs that can cause thrombocytopenia, such as sulfonamides; (5) To exclude false thrombocytopenia caused by EDTA anticoagulants; (6) Patients with or without bleeding tendencies, such as skin hemorrhages, ecchymosis or unexplained nose bleeding, and even serious organ and tissue bleeding; (7) Thrombocytopenia reappeared after re-use of the same antitumor drug 4. The investigator believes that the subject needs to receive hexapopal treatment; 5. ECOG score 0-2 points.
Exclusion criteria
Exclusion criteria: 1. The subjects are conducting clinical intervention studies; 2. Patients with known or expected allergy or intolerance to the active ingredient or excipient of hexapopar; 3. Pregnant or lactating women; 4. Other conditions deemed unsuitable for inclusion in the study by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with minimum PLT >=100×10^9/L after second-cycle tumor therapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients recovered to 100×10^9/L in the first cycle;Proportion of patients with delayed tumor treatment;Proportion of patients with reduced dose of tumor therapy drugs;Proportion of patients receiving platelet transfusion;Treatment-related adverse reactions; | — |
Countries
China
Contacts
Public ContactJia Yitao
Hebei General Hospital
Outcome results
None listed